AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...

Warning! GuruFocus has detected 8 Warning Signs with ABBV. AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on November 4, 2024. This SWOT analysis ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...

Roopal Thakkar; Executive Vice President, Research & Development and Chief Scientific Officer; AbbVie Inc Scott Reents; Chief Financial Officer, Executive Vice President; AbbVie Inc Good morning ...

Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...

Warning! GuruFocus has detected 8 Warning Signs with ABBV. AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on November 4, 2024. This SWOT analysis ...